Yasuma T, Oi S, Choh N, Nomura T, Furuyama N, Nishimura A, Fujisawa Y, Sohda T
Pharmaceutical Research Division and Discovery Research Division, Takeda Chemical Industries, Ltd., 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan.
J Med Chem. 1998 Oct 22;41(22):4301-8. doi: 10.1021/jm9803065.
Cathepsin L, a lysosomal cysteine protease, is secreted by osteoclasts and participates in bone collagen degradation. In a search for cathepsin L inhibitors as antiosteoporotic agents, a series of peptide aldehyde derivatives were prepared by two synthetic approaches, DMSO oxidation of the corresponding alcohol derivatives and DIBAL-H reduction of the corresponding N, O-dimethylhydroxylamide derivatives, and evaluated for inhibitory activity against human cathepsin L and for inhibitory effects on bone resorption. Some of the peptide aldehyde derivatives including alpha-acylamino aldehyde derivatives showed potent activities. Among these compounds, N-(1-naphthalenylsulfonyl-L-isoleucyl-L-tryptophanal (12) was selected as a candidate for further investigation. Compound 12, a potent, selective, and reversible inhibitor of human cathepsin L with an IC50 of 1.9 nM, inhibited the release of Ca2+ and hydroxyproline from bone in in vitro bone culture system and also prevented bone loss in ovariectomized mice at an oral dose of 50 mg/kg.
组织蛋白酶L是一种溶酶体半胱氨酸蛋白酶,由破骨细胞分泌并参与骨胶原降解。为了寻找作为抗骨质疏松药物的组织蛋白酶L抑制剂,通过两种合成方法制备了一系列肽醛衍生物,即相应醇衍生物的二甲基亚砜氧化法和相应的N,O-二甲基羟肟酸酯衍生物的二异丁基氢化铝还原法,并评估了它们对人组织蛋白酶L的抑制活性以及对骨吸收的抑制作用。一些肽醛衍生物,包括α-酰基氨基醛衍生物,表现出强效活性。在这些化合物中,N-(1-萘磺酰基-L-异亮氨酰-L-色氨醛)(12)被选为进一步研究的候选物。化合物12是一种强效、选择性和可逆的人组织蛋白酶L抑制剂,IC50为1.9 nM,在体外骨培养系统中抑制骨中Ca2+和羟脯氨酸的释放,并且在口服剂量为50 mg/kg时也能预防去卵巢小鼠的骨质流失。